- Exchange: NASDAQ GM
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Snapshot for Zogenix Inc (ZGNX)
| Open: | 1.4200 | Day's Range: | 1.4000 - 1.4800 | Volume: | 282,684 |
|---|---|---|---|---|---|
| Previous Close: | 1.4000 | 52wk Range: | 1.1100 - 3.3000 | 1-Yr Rtn: | -31.31% |
Key Statistics for ZGNX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.6500 |
| Est. EPS (USD) (12/2013) | -0.5740 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 148.19 |
| Shares Outstanding (M) | 100.81 |
| 30 Day Average Volume | 569,237 |
| Price/Book (mrq) | - |
| Price/Sale (ttm) | 3.8708 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/08/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ZGNX
Company Profile & Key Executives for ZGNX
Zogenix, Inc. is a specialty pharmaceutical company with proprietary product candidates in late-stage development for the treatment of central nervous system disorders and pain. The Company's products candidates include a product that enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine.
| Roger L HawleyCEO/Co-Founder | Stephen J FarrPresident |
| Cynthia Y RobinsonChief Development Officer | Ann D RhoadsExec VP/CFO/Treasurer/Secy |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ZGNX News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page